Zevra Therapeutics (ZVRA) Asset Writedowns and Impairment (2024 - 2026)

Zevra Therapeutics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $485000.0 for Q1 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $485000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (up 2567.98% YoY) and the FY2025 annual result came in at $11.7 million, up 104.93% from the prior year.
• Asset Writedowns and Impairment was $485000.0 for Q1 2026 at Zevra Therapeutics, up from -$19000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $11.7 million in Q2 2025 and bottomed at -$19000.0 in Q4 2025.
• A 3-year average of $3.2 million and a median of $470500.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• Peak annual rise in Asset Writedowns and Impairment reached 104.17% in 2025, while the deepest fall reached 104.17% in 2025.
• Zevra Therapeutics' Asset Writedowns and Impairment stood at $456000.0 in 2024, then tumbled by 104.17% to -$19000.0 in 2025, then soared by 2652.63% to $485000.0 in 2026.
• Business Quant data shows ZVRA's Asset Writedowns and Impairment at $485000.0 in Q1 2026, -$19000.0 in Q4 2025, and $11.7 million in Q2 2025.